Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant MSCs in Critical COVID-19
NCT04611256Phase 1Unknown
- Sponsor
- Hospital Regional Licenciado Adolfo López Mateos
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mesenchymal stem cells in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hospital Regional Licenciado Adolfo López Mateos. Primary endpoints: Change from baseline in Arterial oxygen saturation up to 25 days and Days to clinical improvement up to 25 days. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04611256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611256.